Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription Articles published in Leukemia Retrieve available abstracts of 113 articles: HTML format

Single Articles

May 2024
1. LIANG JH, Wu YF, Shen HR, Li Y, et al
   Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
   Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02279.
   PubMed     Abstract available
   
   
   
2. WANG TP, Ahn KW, Shadman M, Kaur M, et al
   Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
   Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02242.
   PubMed     Abstract available
   
   
   
3. CHIAPPELLA A, Casadei B, Chiusolo P, Di Rocco A, et al
   Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
   Leukemia. 2024;38:1107-1114.
   PubMed     Abstract available
   
   
   April 2024
4. FISCHER L, Jiang L, Durig J, Schmidt C, et al
   The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
   Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254.
   PubMed     Abstract available
   
   
   
5. REISS DJ, Nakayama Y, Weng AP, Stokes ME, et al
   High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma.
   Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02239.
   PubMed    
   
   
   March 2024
6. OERTEL M, Ziepert M, Frontzek F, Nacke N, et al
   Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
   Leukemia. 2024 Mar 27. doi: 10.1038/s41375-024-02231.
   PubMed     Abstract available
   
   
   
7. GAO LR, Li X, Wang X, Liang Y, et al
   Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma.
   Leukemia. 2024 Mar 19. doi: 10.1038/s41375-024-02227.
   PubMed    
   
   
   
8. LANTERMANS HC, Ma F, Kuil A, van Kesteren S, et al
   The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
   Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02207.
   PubMed     Abstract available
   
   
   February 2024
9. CHEN Z, Huang H, Huang H, Yu L, et al
   Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
   Leukemia. 2024 Feb 20. doi: 10.1038/s41375-024-02171.
   PubMed     Abstract available
   
   
   
10. HOLMQVIST AS, Meng Q, Dai C, Hageman L, et al
    Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02144.
    PubMed     Abstract available
    
    
    
11. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
    Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
    PubMed     Abstract available
    
    
    
12. MANDHAIR HK, Radpour R, Westerhuis M, Banz Y, et al
    Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.
    Leukemia. 2024;38:424-429.
    PubMed    
    
    
    January 2024
13. KNAUFT J, Schenk T, Ernst T, Schnetzke U, et al
    Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.
    Leukemia. 2024 Jan 18. doi: 10.1038/s41375-024-02135.
    PubMed     Abstract available
    
    
    
14. ZALA M, Lipinski B, Costechareyre C, Jarrosson L, et al
    Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos.
    Leukemia. 2024 Jan 15. doi: 10.1038/s41375-024-02150.
    PubMed    
    
    
    
15. LENZ G, Hawkes E, Verhoef G, Haioun C, et al
    Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
    Leukemia. 2024 Jan 10. doi: 10.1038/s41375-023-02133.
    PubMed    
    
    
    
16. LIU B, Zhao X, Zhang S, Li Q, et al
    Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma.
    Leukemia. 2024 Jan 9. doi: 10.1038/s41375-023-02130.
    PubMed     Abstract available
    
    
    
17. ZHANG C, Stelloo E, Barrans S, Cucco F, et al
    Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Leukemia. 2024 Jan 6. doi: 10.1038/s41375-023-02134.
    PubMed     Abstract available
    
    
    December 2023
18. REN W, Wan H, Own SA, Berglund M, et al
    Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis.
    Leukemia. 2023 Dec 29. doi: 10.1038/s41375-023-02120.
    PubMed     Abstract available
    
    
    
19. ZHANG Q, Basappa J, Wang HY, Nunez-Cruz S, et al
    Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
    Leukemia. 2023;37:2436-2447.
    PubMed     Abstract available
    
    
    November 2023
20. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
    Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
    PubMed     Abstract available
    
    
    
21. SUMA S, Suehara Y, Fujisawa M, Abe Y, et al
    Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
    Leukemia. 2023 Nov 27. doi: 10.1038/s41375-023-02093.
    PubMed     Abstract available
    
    
    October 2023
22. FUCHS M, Jacob AS, Kaul H, Kobe C, et al
    Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
    Leukemia. 2023 Oct 16. doi: 10.1038/s41375-023-02064.
    PubMed     Abstract available
    
    
    
23. CASERTA C, Nucera S, Barcella M, Fazio G, et al
    miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
    Leukemia. 2023;37:1994-2005.
    PubMed     Abstract available
    
    
    
24. TIAN Z, Shi C, Yang G, Allen JK, et al
    Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
    Leukemia. 2023;37:2006-2016.
    PubMed     Abstract available
    
    
    September 2023
25. BERNDT SI, Vijai J, Benavente Y, Camp NJ, et al
    Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
    Leukemia. 2023 Sep 4. doi: 10.1038/s41375-023-01978.
    PubMed    
    
    
    
26. METZGEROTH G, Steiner L, Naumann N, Lubke J, et al
    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
    Leukemia. 2023;37:1860-1867.
    PubMed     Abstract available
    
    
    August 2023
27. BRIEST F, Noerenberg D, Hennch C, Yoshida K, et al
    Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
    Leukemia. 2023 Aug 30. doi: 10.1038/s41375-023-02013.
    PubMed     Abstract available
    
    
    
28. SIRCAR A, Singh S, Xu-Monette ZY, Coyle KM, et al
    Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
    Leukemia. 2023 Aug 19. doi: 10.1038/s41375-023-02006.
    PubMed     Abstract available
    
    
    
29. PARAMESWARAN N, Luo L, Zhang L, Chen J, et al
    CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma.
    Leukemia. 2023 Aug 12. doi: 10.1038/s41375-023-01997.
    PubMed     Abstract available
    
    
    
30. KALMBACH S, Grau M, Zapukhlyak M, Leich E, et al
    Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms.
    Leukemia. 2023 Aug 10. doi: 10.1038/s41375-023-01995.
    PubMed     Abstract available
    
    
    July 2023
31. SCHEUBECK G, Jiang L, Hermine O, Kluin-Nelemans HC, et al
    Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
    Leukemia. 2023 Jul 26. doi: 10.1038/s41375-023-01977.
    PubMed     Abstract available
    
    
    June 2023
32. WANG X, Chen C, Vuong D, Rodriguez-Rodriguez S, et al
    Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
    Leukemia. 2023;37:1324-1335.
    PubMed     Abstract available
    
    
    
33. ARMAND M, Degaud M, Tesson B, Laurent C, et al
    Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing.
    Leukemia. 2023;37:1388-1391.
    PubMed    
    
    
    May 2023
34. BERNING P, Schmitz N, Ngoya M, Finel H, et al
    Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
    Leukemia. 2023 May 8:1-10. doi: 10.1038/s41375-023-01924.
    PubMed     Abstract available
    
    
    
35. PASTORET C, Llamas-Gutierrez F, Fouchard M, Moignet A, et al
    Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma.
    Leukemia. 2023 May 4. doi: 10.1038/s41375-023-01922.
    PubMed    
    
    
    
36. SHOMALI W, Colucci P, George TI, Kiladjian JJ, et al
    Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
    Leukemia. 2023;37:981-987.
    PubMed    
    
    
    April 2023
37. XIA Y, Sun T, Li G, Li M, et al
    Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma.
    Leukemia. 2023 Apr 29. doi: 10.1038/s41375-023-01908.
    PubMed     Abstract available
    
    
    
38. ANAGNOSTOU T, Yang ZZ, Jalali S, Kim HJ, et al
    Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma.
    Leukemia. 2023 Apr 28. doi: 10.1038/s41375-023-01911.
    PubMed     Abstract available
    
    
    
39. ARAUJO-AYALA F, Dobano-Lopez C, Valero JG, Nadeu F, et al
    A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
    Leukemia. 2023 Apr 8. doi: 10.1038/s41375-023-01885.
    PubMed     Abstract available
    
    
    
40. HEMMINKI K, Hemminki J, Forsti A, Sud A, et al
    Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.
    Leukemia. 2023;37:854-863.
    PubMed     Abstract available
    
    
    
41. KROONEN JS, de Graaf IJ, Kumar S, Remst DFG, et al
    Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.
    Leukemia. 2023;37:864-876.
    PubMed     Abstract available
    
    
    March 2023
42. MANOS K, Chong G, Keane C, Lee ST, et al
    Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
    Leukemia. 2023 Mar 11. doi: 10.1038/s41375-023-01863.
    PubMed     Abstract available
    
    
    February 2023
43. GOSSAI N, Bhojwani D, Schafer ES, Chang BH, et al
    Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
    Leukemia. 2023 Feb 22. doi: 10.1038/s41375-023-01856.
    PubMed    
    
    
    
44. YUAN R, Wang MY, Bi C, Zhao X, et al
    MCL1 as a therapeutic vulnerability in Burkitt lymphoma.
    Leukemia. 2023 Feb 2. doi: 10.1038/s41375-023-01827.
    PubMed    
    
    
    
45. LIM SK, Peng CC, Low S, Vijay V, et al
    Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
    Leukemia. 2023;37:441-452.
    PubMed     Abstract available
    
    
    January 2023
46. CHIAPPELLA A, Dodero A, Evangelista A, Re A, et al
    Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
    Leukemia. 2023 Jan 18. doi: 10.1038/s41375-022-01780.
    PubMed     Abstract available
    
    
    
47. FRONTZEK F, Staiger AM, Wullenkord R, Grau M, et al
    Molecular profiling of EBV associated diffuse large B-cell lymphoma.
    Leukemia. 2023 Jan 5. doi: 10.1038/s41375-022-01804.
    PubMed     Abstract available
    
    
    
48. JIMENEZ-UBIETO A, Poza M, Martin-Munoz A, Ruiz-Heredia Y, et al
    Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
    Leukemia. 2023 Jan 3. doi: 10.1038/s41375-022-01803.
    PubMed     Abstract available
    
    
    
49. FALINI B, Martino G, Lazzi S
    A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.
    Leukemia. 2023;37:18-34.
    PubMed     Abstract available
    
    
    December 2022
50. CASEY M, Segawa K, Law SC, Sabdia MB, et al
    Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.
    Leukemia. 2022 Dec 20. doi: 10.1038/s41375-022-01794.
    PubMed     Abstract available
    
    
    
51. SHINGAKI S, Koya J, Yuasa M, Saito Y, et al
    Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma.
    Leukemia. 2022 Dec 15. doi: 10.1038/s41375-022-01772.
    PubMed    
    
    
    
52. LI S, Qiu L, Xu J, Lin P, et al
    High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
    Leukemia. 2022 Dec 13. doi: 10.1038/s41375-022-01778.
    PubMed     Abstract available
    
    
    
53. SUREDA-GOMEZ M, Balsas P, Rodriguez ML, Nadeu F, et al
    Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma.
    Leukemia. 2022 Dec 12. doi: 10.1038/s41375-022-01776.
    PubMed     Abstract available
    
    
    
54. WEI W, Song Z, Chiba M, Wu W, et al
    Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
    Leukemia. 2022 Dec 1. doi: 10.1038/s41375-022-01774.
    PubMed     Abstract available
    
    
    
55. HUSBY S, Baech-Laursen C, Eskelund CW, Favero F, et al
    Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
    Leukemia. 2022;36:2912-2916.
    PubMed    
    
    
    November 2022
56. AU-YEUNG RKH, Padilla LA, Zimmermann M, Reinke S, et al
    Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01757.
    PubMed    
    
    
    
57. LI XY, Wu JC, Liu P, Li ZJ, et al
    Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01747.
    PubMed     Abstract available
    
    
    
58. XU W, Berning P, Erdmann T, Grau M, et al
    mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01749.
    PubMed     Abstract available
    
    
    
59. ALARCON TOMAS A, Fein JA, Fried S, Flynn JR, et al
    Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
    Leukemia. 2022 Nov 5. pii: 10.1038/s41375-022-01739.
    PubMed     Abstract available
    
    
    
60. STRATI P, Jallouk AP, Sun R, Choi J, et al
    Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
    Leukemia. 2022;36:2669-2677.
    PubMed     Abstract available
    
    
    October 2022
61. BERNDT SI, Vijai J, Benavente Y, Camp NJ, et al
    Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
    Leukemia. 2022 Oct 22. pii: 10.1038/s41375-022-01711.
    PubMed     Abstract available
    
    
    
62. SEIFERT R, Kersting D, Rischpler C, Sandach P, et al
    Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
    Leukemia. 2022 Oct 14. pii: 10.1038/s41375-022-01713.
    PubMed     Abstract available
    
    
    
63. DRIESSEN J, Kersten MJ, Visser L, van den Berg A, et al
    Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
    Leukemia. 2022 Oct 14. pii: 10.1038/s41375-022-01717.
    PubMed     Abstract available
    
    
    September 2022
64. COX MC, Marcheselli L, Scafetta G, Visco C, et al
    IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.
    Leukemia. 2022 Sep 20. pii: 10.1038/s41375-022-01706.
    PubMed    
    
    
    
65. THOMPSON PA, Jiang X, Banerjee P, Basar R, et al
    A phase two study of high dose blinatumomab in Richter's syndrome.
    Leukemia. 2022;36:2228-2232.
    PubMed     Abstract available
    
    
    August 2022
66. WANG H, Fu BB, Wuxiao ZJ, Li YJ, et al
    A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma.
    Leukemia. 2022 Aug 15. pii: 10.1038/s41375-022-01679.
    PubMed    
    
    
    
67. FREEMAN CL, Pararajalingam P, Jin L, Balasubramanian S, et al
    Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Leukemia. 2022 Aug 13. pii: 10.1038/s41375-022-01658.
    PubMed     Abstract available
    
    
    
68. MENDEVILLE M, Janssen J, Kim Y, van Dijk E, et al
    A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma.
    Leukemia. 2022 Aug 6. pii: 10.1038/s41375-022-01670.
    PubMed    
    
    
    
69. MONTES-MOJARRO IA, Steinhilber J, Griessinger CM, Rau A, et al
    CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.
    Leukemia. 2022;36:2050-2063.
    PubMed     Abstract available
    
    
    July 2022
70. MENTZ M, Keay W, Strobl CD, Antoniolli M, et al
    PARP14 is a novel target in STAT6 mutant follicular lymphoma.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01641.
    PubMed     Abstract available
    
    
    
71. BAZARBACHI A, Boumendil A, Finel H, Khvedelidze I, et al
    Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
    Leukemia. 2022 Jul 15. pii: 10.1038/s41375-022-01639.
    PubMed    
    
    
    
72. HONG Y, Ren T, Wang X, Liu X, et al
    APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
    Leukemia. 2022 Jul 14. pii: 10.1038/s41375-022-01634.
    PubMed     Abstract available
    
    
    
73. MOKER P, Zur Stadt U, Zimmermann M, Alawi M, et al
    Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.
    Leukemia. 2022 Jul 5. pii: 10.1038/s41375-022-01626.
    PubMed    
    
    
    
74. ALAGGIO R, Amador C, Anagnostopoulos I, Attygalle AD, et al
    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
    Leukemia. 2022;36:1720-1748.
    PubMed     Abstract available
    
    
    
75. CHEN L, Zheng Y, Yu K, Chen S, et al
    Changing causes of death in persons with haematological cancers 1975-2016.
    Leukemia. 2022;36:1850-1860.
    PubMed     Abstract available
    
    
    June 2022
76. THUS YJ, Eldering E, Kater AP, Spaargaren M, et al
    Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Leukemia. 2022 Jun 20. pii: 10.1038/s41375-022-01627.
    PubMed     Abstract available
    
    
    
77. LAUER EM, Mutter J, Scherer F
    Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01618.
    PubMed     Abstract available
    
    
    
78. DONG G, Liu X, Wang L, Yin W, et al
    Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.
    Leukemia. 2022 Jun 13. pii: 10.1038/s41375-022-01623.
    PubMed     Abstract available
    
    
    May 2022
79. FERRERI AJM, Cwynarski K, Pulczynski E, Fox CP, et al
    Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
    Leukemia. 2022 May 13. pii: 10.1038/s41375-022-01582.
    PubMed     Abstract available
    
    
    
80. KAMEDA K, Kako S, Kim SW, Usui Y, et al
    Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
    Leukemia. 2022;36:1361-1370.
    PubMed     Abstract available
    
    
    April 2022
81. ZHOU W, Xu Y, Zhang J, Zhang P, et al
    MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.
    Leukemia. 2022 Apr 29. pii: 10.1038/s41375-022-01565.
    PubMed     Abstract available
    
    
    
82. WONG J, Gruber E, Maher B, Waltham M, et al
    Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
    Leukemia. 2022 Apr 22. pii: 10.1038/s41375-022-01571.
    PubMed     Abstract available
    
    
    
83. BAZARBACHI A, Boumendil A, Finel H, Khvedelidze I, et al
    The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
    Leukemia. 2022 Apr 12. pii: 10.1038/s41375-022-01563.
    PubMed     Abstract available
    
    
    March 2022
84. DINNESSEN MAW, Maas CCHM, Tonino SH, Visser O, et al
    Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.
    Leukemia. 2022 Mar 4. pii: 10.1038/s41375-022-01535.
    PubMed    
    
    
    February 2022
85. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2022 Feb 18. pii: 10.1038/s41375-022-01526.
    PubMed    
    
    
    
86. MARCHESI F, Pimpinelli F, Giannarelli D, Ronchetti L, et al
    Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
    Leukemia. 2022;36:588-590.
    PubMed    
    
    
    January 2022
87. LIM TL, Lieberman DB, Davis AR, Loren AW, et al
    Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
    Leukemia. 2022;36:283-287.
    PubMed    
    
    
    November 2021
88. BERTRAM K, Leary PJ, Boudesco C, Fullin J, et al
    Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.
    Leukemia. 2021 Nov 18. pii: 10.1038/s41375-021-01470.
    PubMed     Abstract available
    
    
    
89. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01359.
    PubMed    
    
    
    
90. SPANJAART AM, Ljungman P, de La Camara R, Tridello G, et al
    Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European He
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01466.
    PubMed    
    
    
    October 2021
91. NEWMAN AM, Zaka M, Zhou P, Blain AE, et al
    Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.
    Leukemia. 2021 Oct 21. pii: 10.1038/s41375-021-01444.
    PubMed     Abstract available
    
    
    
92. BROCKELMANN PJ, Muller H, Gillessen S, Yang X, et al
    Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
    Leukemia. 2021 Oct 9. pii: 10.1038/s41375-021-01442.
    PubMed     Abstract available
    
    
    September 2021
93. GARCIA-MARQUEZ MA, Thelen M, Reinke S, Keller D, et al
    Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
    Leukemia. 2021 Sep 28. pii: 10.1038/s41375-021-01421.
    PubMed     Abstract available
    
    
    
94. TAMAKI K, Morishima S, Suzuki S, Shigenari A, et al
    Full-length HLA sequencing in adult T cell leukemia-lymphoma uncovers multiple gene alterations.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01403.
    PubMed    
    
    
    
95. WANG H, Fu BB, Gale RP, Liang Y, et al
    NK-/T-cell lymphomas.
    Leukemia. 2021;35:2460-2468.
    PubMed     Abstract available
    
    
    August 2021
96. VILARRASA-BLASI R, Verdaguer-Dot N, Belver L, Soler-Vila P, et al
    Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma.
    Leukemia. 2021 Aug 28. pii: 10.1038/s41375-021-01389.
    PubMed    
    
    
    
97. DAMASCHIN C, Goergen H, Kreissl S, Plutschow A, et al
    Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
    Leukemia. 2021 Aug 18. pii: 10.1038/s41375-021-01386.
    PubMed    
    
    
    
98. YANG Y, Wang Y, Liu X, He X, et al
    Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
    Leukemia. 2021 Aug 2. pii: 10.1038/s41375-021-01371.
    PubMed    
    
    
    July 2021
99. ROSSI A, Orecchioni S, Falvo P, Tabanelli V, et al
    Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
    Leukemia. 2021 Jul 24. pii: 10.1038/s41375-021-01347.
    PubMed     Abstract available
    
    
    
100. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
     Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert.
     Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01310.
     PubMed    
     
     
     
101. ZHANG Y, Wang Y, Liu Y, Tong C, et al
     Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
     Leukemia. 2021 Jul 16. pii: 10.1038/s41375-021-01345.
     PubMed     Abstract available
     
     
     
102. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
     Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
     Leukemia. 2021 Jul 9. pii: 10.1038/s41375-021-01311.
     PubMed     Abstract available
     
     
     
103. PRITCHETT JC, Yang ZZ, Kim HJ, Villasboas JC, et al
     High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL).
     Leukemia. 2021 Jul 6. pii: 10.1038/s41375-021-01321.
     PubMed     Abstract available
     
     
     
104. HUBSCHMANN D, Kleinheinz K, Wagener R, Bernhart SH, et al
     Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas.
     Leukemia. 2021;35:2002-2016.
     PubMed     Abstract available
     
     
     
105. SASI B, Ethiraj P, Myers J, Lin AP, et al
     Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
     Leukemia. 2021;35:1990-2001.
     PubMed     Abstract available
     
     
     June 2021
106. GRAHAM CE, Jozwik A, Quartey-Papafio R, Ioannou N, et al
     Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
     Leukemia. 2021 Jun 18. pii: 10.1038/s41375-021-01324.
     PubMed    
     
     
     
107. JACHIMOWICZ RD, Klapper W, Glehr G, Muller H, et al
     Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
     Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01314.
     PubMed    
     
     
     
108. POGLIO S, Prochazkova-Carlotti M, Cherrier F, Gros A, et al
     Xenograft and cell culture models of Sezary syndrome reveal cell of origin diversity and subclonal heterogeneity.
     Leukemia. 2021;35:1696-1709.
     PubMed     Abstract available
     
     
     May 2021
109. LITTLE MP, Wakeford R, Zablotska LB, Borrego D, et al
     Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.
     Leukemia. 2021 May 28. pii: 10.1038/s41375-021-01284.
     PubMed     Abstract available
     
     
     
110. WU F, Watanabe N, Tzioni MM, Akarca A, et al
     Thyroid MALT lymphoma: self-harm to gain potential T-cell help.
     Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01289.
     PubMed     Abstract available
     
     
     
111. HE MY, Kridel R
     Treatment resistance in diffuse large B-cell lymphoma.
     Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01285.
     PubMed     Abstract available
     
     
     
112. GOLDMAN S, Barth M, Shiramizu B, Shi Q, et al
     A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
     Leukemia. 2021 May 3. pii: 10.1038/s41375-021-01256.
     PubMed    
     
     
     April 2021
113. CHIHARA D, Miljkovic M, Iyer SP, Vega F, et al
     Targeted based therapy in nodal T-cell lymphomas.
     Leukemia. 2021;35:956-967.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.